Clinical applications of neuroimaging with susceptibility-weighted imaging
✍ Scribed by Vivek Sehgal; Zachary Delproposto; E. Mark Haacke; Karen A. Tong; Nathaniel Wycliffe; Daniel K. Kido; Yingbiao Xu; Jaladhar Neelavalli; Djamel Haddar; Jürgen R. Reichenbach
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 855 KB
- Volume
- 22
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Susceptibility‐weighted imaging (SWI) consists of using both magnitude and phase images from a high‐resolution, three‐dimensional, fully velocity compensated gradient‐echo sequence. Postprocessing is applied to the magnitude image by means of a phase mask to increase the conspicuity of the veins and other sources of susceptibility effects. This article gives a background of the SWI technique and describes its role in clinical neuroimaging. SWI is currently being tested in a number of centers worldwide as an emerging technique to improve the diagnosis of neurological trauma, brain neoplasms, and neurovascular diseases because of its ability to reveal vascular abnormalities and microbleeds. J. Magn. Reson. Imaging 2005. © 2005 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract ## Purpose: To extend susceptibility weighted imaging (SWI) to multiple echoes with an adapted homodyne filtering of phase images for the computation of venograms with improved signal to noise ratio (SNR) and contrast to noise ratio (CNR) and to produce high resolution maps of R~2~\* r
## Abstract Susceptibility weighted imaging (SWI) is a new MRI technique that can identify calcification by using phase images. We present a single case with a partially calcified oligodendroglioma, multiple calcified cysticercosis lesions, and multiple physiologic calcifications in the same patien
## Abstract ## Purpose To evaluate the clinical value of diffusion‐weighted imaging (DWI) and dynamic MRI in combination with T2‐weighted imaging (T2W) for the detection of prostate cancer. ## Materials and Methods A total of 83 patients with elevated serum prostate specific antigen (PSA) levels